Hefei Lifeon Pharmaceutical Co., Ltd.
SZSE:003020.SZ
25.2 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,882.454 | 2,579.34 | 2,273.254 | 1,894.291 | 1,650.032 | 1,424.581 | 1,166.572 | 1,028.168 | 962.167 | 877.72 | 733.321 |
| Cost of Revenue
| 938.751 | 1,615.063 | 1,366.086 | 1,260.655 | 1,132.806 | 998.93 | 908.953 | 839.693 | 786.348 | 709.416 | 598.252 |
| Gross Profit
| 943.703 | 964.278 | 907.169 | 633.636 | 517.225 | 425.651 | 257.62 | 188.475 | 175.818 | 168.304 | 135.069 |
| Gross Profit Ratio
| 0.501 | 0.374 | 0.399 | 0.334 | 0.313 | 0.299 | 0.221 | 0.183 | 0.183 | 0.192 | 0.184 |
| Reseach & Development Expenses
| 79.912 | 73.804 | 65.858 | 43.31 | 37.444 | 23.789 | 18.388 | 11.795 | 9.193 | 9.097 | 6.711 |
| General & Administrative Expenses
| 21.907 | 15.599 | 11.024 | 14.115 | 8.636 | 16.12 | 6.15 | 22.441 | 23.499 | 21.243 | 17.531 |
| Selling & Marketing Expenses
| 598.452 | 616.386 | 605.241 | 393.81 | 328.061 | 258.873 | 118.996 | 71.389 | 85.666 | 87.129 | 67.264 |
| SG&A
| 651.009 | 631.984 | 616.266 | 407.925 | 336.696 | 274.994 | 125.146 | 93.83 | 109.165 | 108.373 | 84.795 |
| Other Expenses
| -5.84 | 47.67 | 42.462 | 26.792 | 23.995 | 0.153 | 1.517 | 6.033 | 5.771 | 4.3 | 2.512 |
| Operating Expenses
| 736.761 | 753.458 | 724.586 | 478.027 | 398.136 | 318.338 | 164.153 | 110.472 | 112.763 | 111.851 | 87.765 |
| Operating Income
| 206.942 | 240.055 | 192.454 | 157.438 | 118.844 | 108.274 | 89.955 | 75.138 | 58.335 | 50.256 | 37.93 |
| Operating Income Ratio
| 0.11 | 0.093 | 0.085 | 0.083 | 0.072 | 0.076 | 0.077 | 0.073 | 0.061 | 0.057 | 0.052 |
| Total Other Income Expenses Net
| 49.416 | -0.232 | 2.381 | -0.498 | 2.78 | 1.114 | -1.994 | 3.167 | 0.783 | -1.925 | -7.36 |
| Income Before Tax
| 256.358 | 239.823 | 194.835 | 156.941 | 121.624 | 108.427 | 91.472 | 81.17 | 63.838 | 54.527 | 39.943 |
| Income Before Tax Ratio
| 0.136 | 0.093 | 0.086 | 0.083 | 0.074 | 0.076 | 0.078 | 0.079 | 0.066 | 0.062 | 0.054 |
| Income Tax Expense
| 23.534 | 30.216 | 22.608 | 21.825 | 16.483 | 16.763 | 14.653 | 13.708 | 11.984 | 9.712 | 7.101 |
| Net Income
| 226.673 | 209.249 | 172.227 | 135.116 | 105.141 | 91.664 | 76.819 | 67.463 | 53.824 | 47.024 | 36.693 |
| Net Income Ratio
| 0.12 | 0.081 | 0.076 | 0.071 | 0.064 | 0.064 | 0.066 | 0.066 | 0.056 | 0.054 | 0.05 |
| EPS
| 1.44 | 1.34 | 1.1 | 0.86 | 0.67 | 0.81 | 0.69 | 0.6 | 0.49 | 0.42 | 0.33 |
| EPS Diluted
| 1.44 | 1.34 | 1.1 | 0.86 | 0.67 | 0.81 | 0.69 | 0.6 | 0.49 | 0.42 | 0.33 |
| EBITDA
| 254.284 | 283.352 | 236.075 | 174.599 | 139.031 | 127.1 | 108.801 | 97.294 | 75.054 | 69.739 | 65.233 |
| EBITDA Ratio
| 0.135 | 0.11 | 0.104 | 0.092 | 0.084 | 0.089 | 0.093 | 0.095 | 0.078 | 0.079 | 0.089 |